The Institute for Clinical and Economic Review (ICER) is soliciting patient input regarding migraine to help formulate their recommendations regarding the cost effectiveness of new emerging treatments. Insurance companies will use ICER’s report (as well as other information) when determining if they will cover the new CGRP antibodies when they are marketed, what tier the new medicines will be in on the plans’ formularies, and what types of prior authorization or step therapy will be required. Your opinions are greatly needed to make the report accurate during a public commentary period that is going on now.
The deadline for the first round of input is November 30, 2017. We know this deadline is coming up very quickly. So please act now by submitting public comments by Direct email at firstname.lastname@example.org (no word limit). Or you can complete an Online form of 10 questions available on the ICER website at https://icer-review.org/
WHAT TO SAY
You can share whatever message you have that will help the reviewers understand that migraine is not a trivial disease. Some of the points we think are important for our community to address are:
- Migraine disease is complex: Explain migraine, including its disabling impact, the large number of people affected and its characteristics such as severity, duration and associated symptoms (nausea, vomiting, light and noise sensitivity, etc).
- Disabling nature of migraine: Discuss the neg
ative physical and quality of life impacts of migraine disease (e.g. impact on ability to work, harmed social relationships, limitations on self-care and burden on caregivers).
- Disease resistance to current treatments: Describe your personal journey, note challenges with diagnosis and ineffective treatments, detail harmful side-effects of medicines you may have used for migraine, and common barriers to care faced by migraine patients.
- Need for new treatments: Define need for more effective treatments with better side-effect profiles. Address factors such as: quality of life, depression, isolation, the need for reduced usage of opioids, and the high medical costs and ineffectiveness of emergency room services for migraine patients.
Please join this effort to make sure every person who fights the daily fight of migraine has access to medications that could change their lives! Thanks in advance for your contribution!
Timothy R Smith, MD RPh